{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:39:36Z","timestamp":1794335976785,"version":"4.9.0"},"reference-count":104,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Adoptive transfer of virus-specific T cells (VSTs) has been used for managing viral diseases in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation and solid organ transplantation. Clinical trials targeting viruses such as cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus have demonstrated effective viral control without the toxicities associated with conventional antiviral therapies. This review explores the manufacturing, feasibility, safety, and efficacy of VSTs, complemented by 2 case studies illustrating their real-world application. We examine recent advancements in VST manufacturing that broaden their accessibility and applicability to a wider range of viral infections and immunocompromised populations. Key safety considerations, including cytokine release syndrome and graft-versus-host disease, are discussed. Lastly, we assess the expanding applications of VSTs against emerging viral targets, such as COVID-19, and address current barriers to their implementation beyond the research setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013727","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:55:02Z","timestamp":1756306502000},"page":"5965-5975","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations"],"prefix":"10.1182","volume":"9","author":[{"given":"Navid","family":"Djassemi","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9093","authenticated-orcid":false,"given":"Benjamin","family":"Hanisch","sequence":"additional","affiliation":[{"name":"2Division of Infectious Diseases, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Motta","sequence":"additional","affiliation":[{"name":"3Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Maghzian","sequence":"additional","affiliation":[{"name":"3Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-0490","authenticated-orcid":false,"given":"Anant","family":"Vatsayan","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-6881","authenticated-orcid":false,"given":"Jessica R.","family":"Durkee-Shock","sequence":"additional","affiliation":[{"name":"4Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-3085","authenticated-orcid":false,"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[{"name":"3Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC"},{"name":"5Division of Allergy and Immunology, Children\u2019s National Hospital, Washington, DC"},{"name":"6GW Cancer Center, George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"3","key":"2025120910112614700_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1701563","article-title":"Adenovirus infection after pediatric bone marrow transplantation","volume":"23","author":"Hale","year":"1999","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2025120910112614700_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00006454-198802000-00009","article-title":"Viral infections in pediatric bone marrow transplant patients","volume":"7","author":"Wasserman","year":"1988","journal-title":"Pediatr Infect Dis J"},{"issue":"26","key":"2025120910112614700_bib3","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2025120910112614700_bib4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2019000924","article-title":"Virus-specific T-cell therapies for patients with primary immune deficiency","volume":"135","author":"Keller","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2025120910112614700_bib5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2022008219","article-title":"Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease","volume":"7","author":"Kinoshita","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025120910112614700_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-024-00930-x","article-title":"Applications of cell therapy in the treatment of virus-associated cancers","volume":"21","author":"Toner","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"285","key":"2025120910112614700_bib7","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"issue":"242","key":"2025120910112614700_bib8","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"23","key":"2025120910112614700_bib9","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2025120910112614700_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"issue":"11","key":"2025120910112614700_bib11","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025120910112614700_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"9331","key":"2025120910112614700_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"The Lancet"},{"issue":"2","key":"2025120910112614700_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"2025120910112614700_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"issue":"18","key":"2025120910112614700_bib16","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2025120910112614700_bib17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.26535","article-title":"Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy","volume":"97","author":"Pei","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2025120910112614700_bib18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jix357","article-title":"Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus","volume":"216","author":"Pei","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"2025120910112614700_bib19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ana.26020","article-title":"Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy","volume":"89","author":"Berzero","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"2025120910112614700_bib20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol"},{"issue":"9","key":"2025120910112614700_bib21","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2025120910112614700_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2025120910112614700_bib23","doi-asserted-by":"crossref","first-page":"e163548","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"issue":"20","key":"2025120910112614700_bib24","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2010-11-320226","article-title":"HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo","volume":"117","author":"Chapuis","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2025120910112614700_bib25","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2025120910112614700_bib26","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv"},{"issue":"16","key":"2025120910112614700_bib27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120910112614700_bib28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","article-title":"Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution","volume":"19","author":"Clancy","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2025120910112614700_bib29","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"2025120910112614700_bib30","doi-asserted-by":"crossref","first-page":"1251593","DOI":"10.3389\/fimmu.2023.1251593","article-title":"Prevention of CMV\/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I\/IIa MULTIVIR-01 study","volume":"14","author":"Gerbitz","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"2025120910112614700_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"3","key":"2025120910112614700_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0033-1333749","article-title":"Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation","volume":"225","author":"Feucht","year":"2013","journal-title":"Klin Padiatr"},{"issue":"1","key":"2025120910112614700_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcyt.2020.08.006","article-title":"Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay","volume":"23","author":"Lazarski","year":"2021","journal-title":"Cytotherapy"},{"issue":"11","key":"2025120910112614700_bib34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamaneurol.2024.3324","article-title":"Directly isolated allogeneic virus-specific T cells in progressive multifocal leukoencephalopathy","volume":"81","author":"M\u00f6hn","year":"2024","journal-title":"JAMA Neurol"},{"issue":"10","key":"2025120910112614700_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2025120910112614700_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS Prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J Immunother"},{"issue":"3","key":"2025120910112614700_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2025120910112614700_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"issue":"1","key":"2025120910112614700_bib39","first-page":"65","article-title":"CMV-specific T-cells for treatment of CMV infection after hematopoietic stem cell transplantation in a pediatric case: first application in Turkey","volume":"37","author":"Celilova","year":"2020","journal-title":"Turk J Haematol"},{"issue":"1","key":"2025120910112614700_bib40","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1002\/hem3.40","article-title":"On behalf of the SFGM-TC: real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients","volume":"8","author":"Leroyer","year":"2024","journal-title":"Hemasphere"},{"issue":"17","key":"2025120910112614700_bib41","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025120910112614700_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2025120910112614700_bib43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2025120910112614700_bib44","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"issue":"10","key":"2025120910112614700_bib45","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"issue":"1","key":"2025120910112614700_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2025120910112614700_bib47","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2003-05-1433","article-title":"Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy","volume":"105","author":"Trivedi","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2025120910112614700_bib48","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/bloodadvances.2022007005","article-title":"Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy","volume":"6","author":"Hasan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025120910112614700_bib49","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"issue":"26","key":"2025120910112614700_bib50","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2025120910112614700_bib51","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"2025120910112614700_bib52","doi-asserted-by":"crossref","first-page":"e165476","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"2025120910112614700_bib53","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","article-title":"Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol","volume":"8","author":"Nikiforow","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025120910112614700_bib54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein\u2013Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025120910112614700_bib55","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","article-title":"Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant","volume":"24","author":"Khoury","year":"2024","journal-title":"Am J Transpl"},{"issue":"24","key":"2025120910112614700_bib56","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.20.02608","article-title":"Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025120910112614700_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2141.2002.03683.x","article-title":"Safety of allogeneic Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma","volume":"118","author":"Sun","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120910112614700_bib58","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller","year":"2024","journal-title":"Nat Commun"},{"issue":"31","key":"2025120910112614700_bib59","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025120910112614700_bib60","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"8","author":"Dadwal","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2025120910112614700_bib61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025120910112614700_bib62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/bloodadvances.2020002735","article-title":"Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses","volume":"5","author":"Fabrizio","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2025120910112614700_bib63","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1600-6143.2009.02672.x","article-title":"Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy","volume":"9","author":"Brestrich","year":"2009","journal-title":"Am J Transpl"},{"issue":"4","key":"2025120910112614700_bib64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025120910112614700_bib65","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunol"},{"issue":"5","key":"2025120910112614700_bib66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.healun.2015.12.031","article-title":"Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation","volume":"35","author":"Pierucci","year":"2016","journal-title":"J Heart Lung Transpl"},{"issue":"5","key":"2025120910112614700_bib67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","article-title":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children\u2019s Oncology Group study","volume":"8","author":"Wistinghausen","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2025120910112614700_bib68","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1600-6143.2005.00854.x","article-title":"Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells","volume":"5","author":"Comoli","year":"2005","journal-title":"Am J Transpl"},{"issue":"4","key":"2025120910112614700_bib69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOT.0000000000000206","article-title":"Organ-specific differences in achieving tolerance","volume":"20","author":"Madariaga","year":"2015","journal-title":"Curr Opin Organ Transpl"},{"issue":"3","key":"2025120910112614700_bib70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CJI.0000000000000031","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J Immunother"},{"issue":"3","key":"2025120910112614700_bib71","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transpl"},{"issue":"2","key":"2025120910112614700_bib72","doi-asserted-by":"crossref","first-page":"e13133","DOI":"10.1111\/petr.13133","article-title":"Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children","volume":"22","author":"Chiou","year":"2018","journal-title":"Pediatr Transpl"},{"issue":"22","key":"2025120910112614700_bib73","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025120910112614700_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett"},{"issue":"6","key":"2025120910112614700_bib75","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ajcp\/103.6.748","article-title":"Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin","volume":"103","author":"Weissmann","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"2025120910112614700_bib76","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3389\/fimmu.2018.01475","article-title":"Dissecting Epstein-Barr virus-specific T-cell responses after allogeneic EBV-specific T-cell transfer for central nervous system posttransplant lymphoproliferative disease","volume":"9","author":"Schultze-Florey","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"2025120910112614700_bib77","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaip.2022.01.042","article-title":"Morbidity, mortality, and therapeutics in combined immunodeficiency: data from the USIDNET Registry","volume":"10","author":"Durkee-Shock","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2025120910112614700_bib78","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2025120910112614700_bib79","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10875-020-00961-w","article-title":"Failure of viral-specific T cells administered in pre-transplant settings in children with inborn errors of immunity","volume":"41","author":"Alonso","year":"2021","journal-title":"J Clin Immunol"},{"key":"2025120910112614700_bib80","doi-asserted-by":"crossref","first-page":"721917","DOI":"10.3389\/fimmu.2021.721917","article-title":"Unmanipulated matched sibling donor hematopoietic cell transplantation in TBX1 congenital athymia: a lifesaving therapeutic approach when facing a systemic viral infection","volume":"12","author":"Chitty-Lopez","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"2025120910112614700_bib81","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.bbmt.2018.04.030","article-title":"Antiviral T cells for adenovirus in the pretransplant period: a bridge therapy for severe combined immunodeficiency","volume":"24","author":"Miller","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025120910112614700_bib82","doi-asserted-by":"crossref","first-page":"e28126","DOI":"10.1002\/pbc.28126","article-title":"EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects","volume":"67","author":"Rubinstein","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2025120910112614700_bib83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2025120910112614700_bib84","doi-asserted-by":"crossref","first-page":"801281","DOI":"10.3389\/fimmu.2021.801281","article-title":"Case report: fatal complications of BK virus-hemorrhagic cystitis and severe cytokine release syndrome following BK virus-specific T-cells","volume":"12","author":"Holland","year":"2021","journal-title":"Front Immunol"},{"issue":"22","key":"2025120910112614700_bib85","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025120910112614700_bib86","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41467-024-47056-3","article-title":"Secondary bone marrow graft loss after third-party virus-specific T cell infusion: case report of a rare complication","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2025120910112614700_bib87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2003-07-2603","article-title":"Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants","volume":"103","author":"Randolph","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2025120910112614700_bib88","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/bloodadvances.2018019513","article-title":"Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"2025120910112614700_bib89","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/00007890-199706150-00027","article-title":"Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes","volume":"63","author":"Emanuel","year":"1997","journal-title":"Transplantation"},{"issue":"18","key":"2025120910112614700_bib90","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2025120910112614700_bib91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother"},{"issue":"3","key":"2025120910112614700_bib92","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"issue":"11","key":"2025120910112614700_bib93","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2025120910112614700_bib94","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2025120910112614700_bib95","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2025120910112614700_bib96","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025120910112614700_bib97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/infdis\/jiad423","article-title":"The effects of human immunodeficiency virus type 1 (HIV-1) antigen-expanded specific T-cell therapy and vorinostat on persistent HIV-1 infection in people with HIV on antiretroviral therapy","volume":"229","author":"Gay","year":"2024","journal-title":"J Infect Dis"},{"issue":"8","key":"2025120910112614700_bib98","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jcyt.2019.06.008","article-title":"Generation of Zika virus-specific T cells from seropositive and virus-na\u00efve donors for potential use as an autologous or \u201coff-the-shelf\u201d immunotherapeutic","volume":"21","author":"Hanajiri","year":"2019","journal-title":"Cytotherapy"},{"issue":"15","key":"2025120910112614700_bib99","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2024013344","article-title":"Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19","volume":"8","author":"Grosso","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"2025120910112614700_bib100","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ymthe.2018.08.015","article-title":"HIV-specific, ex vivo expanded T cell therapy: feasibility, safety, and efficacy in ART-suppressed HIV-infected individuals","volume":"26","author":"Sung","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"2025120910112614700_bib101","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1038\/s41467-025-59810-2","article-title":"Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study","volume":"16","author":"Sohai","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"2025120910112614700_bib102","doi-asserted-by":"crossref","first-page":"e30429","DOI":"10.1002\/pbc.30429","article-title":"Viral-specific T cells for cytomegalovirus retinitis following hematopoietic stem cell transplantation: a success story","volume":"70","author":"Montiel-Esparza","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2025120910112614700_bib103","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/bloodadvances.2019000121","article-title":"Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis","volume":"3","author":"Seo","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2025120910112614700_bib104","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2019.04.006","article-title":"Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant","volume":"144","author":"Auletta","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5965\/2423271\/blooda_adv-2024-013727-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5965\/2423271\/blooda_adv-2024-013727-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:19:06Z","timestamp":1765293546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/5965\/546897\/Harnessing-virus-specific-T-cells-expanding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":104,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013727","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,11,26]]}}}